Welcome to our dedicated page for Anaptysbio SEC filings (Ticker: ANAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AnaptysBio, Inc. (ANAB) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports on Form 8-K and other key documents filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company focused on immunology therapeutics, AnaptysBio uses these filings to report material events related to its clinical programs, collaborations, capital allocation decisions and strategic plans.
Recent Form 8-K filings describe several categories of information. Some filings report results of operations and financial condition, where AnaptysBio furnishes press releases detailing quarterly financial results and business updates. Others fall under Regulation FD disclosure, such as filings that provide updated corporate investor presentations or slide decks used in conference calls discussing programs like ANB033 or the company’s broader pipeline.
Additional 8-Ks highlight other events, including board authorization of amendments to the company’s stock repurchase plan and the board’s approval of plans to explore separating AnaptysBio’s business into two independent, publicly traded companies by the end of 2026. Filings also cover the company’s Verified Complaint in Delaware Chancery Court against Tesaro and GSK concerning the Collaboration and Exclusive License Agreement for Jemperli, as well as references to Tesaro and GSK’s complaint against AnaptysBio.
For investors analyzing ANAB, these filings help clarify how AnaptysBio reports litigation developments, collaboration terms, royalty monetization arrangements, and major strategic decisions. On Stock Titan, SEC documents are paired with AI-powered summaries that explain the main points of each filing in plain language, highlight notable items such as litigation updates or changes to repurchase plans, and make it easier to scan multiple 8-Ks and other forms without reading every line of legal text.
AnaptysBio, Inc. (ANAB) Form 144 shows an intended sale of 10,231 common shares with an aggregate market value of $200,712.78 to be executed on or about 08/08/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing states these shares were acquired by a stock option exercise on 08/08/2025 with payment in cash. The notice also discloses prior sales by the same person, HOLLINGS C RENTON: 20,925 shares sold 07/02/2025 for $493,189.70 and 3,015 shares sold 06/18/2025 for $72,269.55. The signer represents there is no undisclosed material adverse information.
AnaptysBio is registering 1,650,000 additional shares of its common stock to be available under the Amended and Restated 2017 Equity Incentive Plan following stockholder approval. The filing makes those shares available for future awards to employees and directors and incorporates prior S-8 registrations and related company filings on file with the SEC.
Morgan Stanley and its subsidiary Morgan Stanley Capital Services LLC filed a Schedule 13G on 08/05/2025 disclosing a combined passive stake of 1,845,002 ANAB shares (6.3 % of outstanding) as of 06/30/2025. The parent company reports shared voting power over 1,841,919 shares and shared dispositive power over 1,845,002 shares; it holds no sole voting or dispositive authority.
The subsidiary individually owns 1,525,502 shares (5.2 %) with fully shared voting and dispositive power. The filing is made under Rule 13d-1(b), classifying Morgan Stanley as a parent holding company/control person (HC, CO) and the subsidiary as a broker-dealer (BD, CO). Both certify the shares were acquired in the ordinary course of business and not for the purpose of influencing control of AnaptysBio.
Director Dennis M. Fenton of AnaptysBio reported a significant insider transaction on June 18, 2025. The filing details:
- Sale of 3,015 shares of Common Stock at $23.97 per share
- Transaction was executed under a Rule 10b5-1 trading plan established on March 22, 2024
- The sale was primarily to satisfy tax obligations related to restricted stock unit vesting on June 15, 2025
- Following the transaction, Fenton retains direct ownership of 4,965 shares
This transaction appears to be a planned sale for tax purposes rather than a discretionary trade, as evidenced by the pre-established 10b5-1 plan. The sale represents a partial liquidation of Fenton's holdings, maintaining a significant ownership position in the company.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
